Peer-reviewed report on Moderna COVID-19 vaccine publishes

Peer-reviewed report on Moderna COVID-19 vaccine publishes (

The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19. Investigators identified no safety concerns and no evidence of vaccine-associated enhanced respiratory disease (VAERD).

The vaccine was co-developed by Moderna, Inc., a biotechnology company based in Cambridge, Massachusetts, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Moderna(link is external) and NIAID previously shared initial results from the COVE trial. On Dec. 18, 2020, the FDA issued an Emergency Use Authorization(link is external) allowing Moderna to make the vaccine available for the prevention of COVID-19 in adults in the United States.

Read the complete Press Release on

Submitted by Admin on Wed, 12/30/2020 - 19:21